According to The Insight Partners, Global Sartans Market is expected to grow from US$30.83 billion in 2025 to US$36.43 billion by 2034, registering a CAGR of 2.11% during the forecast period from 2026 to 2034 . The market expansion is largely attributed to the increasing global burden of cardiovascular diseases, growing aging populations, and the rising demand for effective blood pressure management therapies. Sartans have become a preferred treatment option due to their ability to lower blood pressure while reducing the risk of heart attacks, strokes, and kidney complications in high-risk patients.

Market Drivers Fueling Sartans Market Growth

Rising Global Prevalence of Hypertension

A key factor fueling the growth of the Sartans Market is the rising global prevalence of hypertension. Factors such as sedentary lifestyles, poor dietary choices, obesity, smoking, and chronic stress have contributed to an increasing number of individuals developing high blood pressure. As hypertension continues to be a major risk factor for cardiovascular diseases and premature death, the demand for effective blood pressure management therapies, including sartans, is expected to remain strong.

Get a Sample PDF - https://www.theinsightpartners.com/sample/TIPRE00021908

Healthcare organizations and governments are increasingly emphasizing early diagnosis and treatment of hypertension, which is encouraging greater prescription rates of ARBs. As a result, sartans continue to play a critical role in long-term disease management strategies.

Growing Burden of Cardiovascular Diseases

Cardiovascular diseases remain a major public health concern globally. Conditions such as heart failure, coronary artery disease, and stroke often require comprehensive blood pressure management to reduce complications. Sartans are widely prescribed due to their proven efficacy in lowering blood pressure and protecting cardiovascular health.

The growing number of patients requiring chronic cardiovascular care is creating strong demand for ARB therapies. Additionally, clinical evidence supporting the cardiovascular protective benefits of sartans is encouraging healthcare professionals to adopt these medications as part of standard treatment protocols.

Increasing Geriatric Population

The global aging population is another significant driver of market growth. Older adults are more susceptible to hypertension, heart disease, diabetes, and kidney disorders, increasing the demand for effective and well-tolerated treatment options. Sartans offer several advantages for elderly patients, including improved tolerability and reduced incidence of certain side effects compared to alternative therapies.

As life expectancy continues to rise across developed and developing countries, the number of patients requiring long-term antihypertensive treatment is expected to increase, supporting sustained market expansion through 2034.

Growing Preference for ARBs Over Alternative Therapies

Healthcare providers increasingly prefer sartans due to their favorable safety profile and effectiveness. Compared with some other antihypertensive drug classes, sartans are associated with lower rates of adverse effects such as persistent cough, improving patient adherence to treatment.

Better patient compliance leads to improved clinical outcomes and reduced healthcare costs associated with unmanaged hypertension. This growing preference among physicians and patients continues to support market demand globally.

Expansion of Healthcare Access in Emerging Economies

Emerging economies across Asia-Pacific, Latin America, and parts of the Middle East are witnessing significant improvements in healthcare infrastructure and pharmaceutical accessibility. Increased healthcare spending, rising health awareness, and government initiatives focused on chronic disease management are contributing to higher diagnosis and treatment rates for hypertension.

As access to essential cardiovascular medications expands in these regions, pharmaceutical manufacturers are expected to benefit from new growth opportunities, further strengthening the global Sartans Market.

Technological and Pharmaceutical Advancements

Continuous research and development activities are supporting innovation within the antihypertensive drug market. Pharmaceutical companies are focusing on improved formulations, combination therapies, and enhanced drug delivery methods to optimize treatment outcomes. Combination therapies involving sartans and other cardiovascular medications are gaining popularity as they simplify treatment regimens and improve patient compliance.

Moreover, advances in digital healthcare and remote patient monitoring are enabling healthcare providers to track blood pressure more effectively, resulting in earlier intervention and increased medication adherence.

Competitive Landscape

The Sartans Market remains highly competitive, with several global pharmaceutical companies actively participating in product development, commercialization, and market expansion initiatives. Leading market players are investing in strategic collaborations, research activities, and portfolio diversification to strengthen their market positions.

Key Players in the Sartans Market

• Pfizer
• Novartis
• Merck
• Astra Zeneca
• Johnson and Johnson
• Eli Lilly
• Sanofi
• Bristol-Myers Squibb
• Bayer
• GSK
• Teva Pharmaceutical

These companies continue to focus on innovation, regulatory approvals, and geographic expansion strategies to address the growing demand for cardiovascular therapies worldwide.

Future Outlook

The future of the Sartans Market appears promising despite moderate growth rates. Rising hypertension prevalence, increasing cardiovascular disease incidence, expanding healthcare access, and growing awareness regarding preventive healthcare will continue to drive market demand through 2034. Furthermore, the development of advanced treatment approaches and combination therapies is expected to create additional opportunities for pharmaceutical manufacturers.

As healthcare systems increasingly prioritize chronic disease management and cardiovascular risk reduction, sartans will remain a cornerstone therapy in hypertension treatment. Their established clinical effectiveness, safety profile, and broad therapeutic applications position the market for stable and sustained growth over the forecast period.

About Us

The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us

Ankit Mathur | The Insight Partners
Email: ankit.mathur@theinsightpartners.com
Phone: +1-646-491-9876

Also Available in: Korean | German | Japanese | French | Chinese | Italian | Spanish